32 results
Thumbnail

D3.357 - Revealing an Underlying Inborn Error of Immunity in Pediatric Granulomatous Disease: A Case of STAT1 Loss-of-Function–Associated Mendelian Susceptibility to Mycobacterial Disease after BCG Vaccination

Thumbnail

D3.361 - Pulmonary Embolism in a Patient with Hyper IgE (Job) Syndrome Associated with Genetic Thrombophilia: A Rare Case

Thumbnail

D3.362 - Ulcerative Colitis Developing in an Immunodeficiency Patient with CD19 Gene Mutation: A Case Report

Thumbnail

D3.363 - Systemic Lupus Erythematosus in a Patient with Hyper IgM Syndrome

Thumbnail

D3.366 - Experience With Berotralstat In The First Turkish Patients

Thumbnail

D3.367 - Clinical and immunological heterogeneity of 22q11.2 deletion syndrome in children from the Republic of Moldova

Thumbnail

D3.368 - Selective IgE Deficiency in Children: 10-Year Experience

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut

Thumbnail

D3.448 - Use of Sebetralstat as Short-term Prophylaxis for Patients with Hereditary Angioedema: Results from the KONFIDENT-S Study

Thumbnail

D3.507 - Impact of chemical warfare agents on immune response